IL13RA2 and glioblastoma: After showing favorable results in a Phase 1 trial (98), ICT-107, an autologous DC vaccine with six synthetic GBM-associated peptides including IL-13Rα2, was evaluated in a double-blinded, randomized phase 2 clinical trial in newly diagnosed patients with GBM.